Ombitasvir, Paritaprevir, Ritonavir and Dasabuvir (Oral)

Prescribed to patients with a chronic hepatitis C infection, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir is used as a combination medicine and may be given alongside Ribavirin.

Overview

When individuals are first infected with the hepatitis C virus, they don't always exhibit symptoms. In some cases, patients may experience abdominal pain, fever and/or dark urine but these symptoms are generally mild, if they occur at all. Once patients have contracted the virus, it tends to persist in the vast majority of cases. Mainly affecting the liver, the hepatitis C infection becomes chronic and causes a number of serious complications.

Although it can take years for the complications of hepatitis C infections to become apparent, patients may develop liver disease and/or cirrhosis of the liver as a result of the virus. Patients with cirrhosis may also develop dilated blood vessels in the stomach and esophagus, liver cancer and/or liver disease.

Despite the seriousness of the condition, there is not currently a vaccine to protect against the hepatitis C virus. However, the virus is normally transmitted via blood-to-blood contact and more accurate screening processes have reduced the number of people affected by hepatitis C. Blood donors are tested prior to giving blood, for example, and donated blood is tested again before being given to a patient. However, the use of unsterilized equipment, 'needlestick' injuries, the sharing of medical equipment and intravenous drug use can result in the transmission of the hepatitis C virus.

When patients have had the virus for a period of six months or longer, it is deemed to be chronic. In these cases, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir can be used to treat patients and is successful in the vast majority of instances. As a combination medicine, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir contains various active ingredients, with each one targeting the virus in a different way.

Ombitasvir is an antiviral drug and inhibits the non-structural protein 5A in the virus. Paritaprevir is an acylsulfonamide inhibitor which affects the NS3-4A serine protease, whilst Ritonavir is an antiretroviral medicine that inhibits cytochrome P450-3A4. Found in the liver, cytochrome P450-3A4 metabolizes protease inhibitors. When inhibited by Ritonavir, the enzyme is unable to take effect and the amount of hepatitis C virus in the patient's system is reduced. Dasabuvir is also an antiviral medicine and works by inhibiting NS5B palm polymerase, which prevents the hepatitis C virus from replicating and infecting new cells.

Sometimes used in conjunction with Ribavirin, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir is predominantly used to treat patients with a chronic hepatitis C infection, caused by the virus genotype 1 and 4. As the virus can be caused by various different genotypes, patients may be given an alternative combination of medications if they have developed the infection as a result of a different virus genotype.

Although hepatitis C infections can be difficult to diagnose, medical tests are becoming more accurate. Once the patient has been diagnosed and the infection has been classed as chronic, treatment should begin as soon as possible. As Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir is successful in treating the majority of patients, swift treatment can help to prevent further damage occurring to the liver and may prevent patients from needing more invasive treatments, such as a liver transplant.

Conditions Treated

  • Chronic hepatitis C infection

Type Of Medicine

  • Antiviral

Side Effects

Although Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir is generally well-tolerated, patients may experience some side-effects when taking this medication. In many cases, these side effects are more pronounced when patients first start using the medication but decrease over time. When patients first start using Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, for example, they may exhibit:

  • Loss of lack or strength
  • Difficulty sleeping
  • Rash on the skin
  • Itching skin

If the above symptoms are fairly mild and are not bothersome, the patient may not need additional medical attention. However, if the symptoms persist or are severe, patients should obtain medical assistance.

In addition to this, patients should obtain immediate medical advice if they experience the following side effects when taking Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir:

  • Stomach or abdominal pain
  • Unusual weakness or tiredness
  • Bloating of the stomach or abdomen
  • Dark urine
  • Irritated, red eyes
  • Light-colored stools
  • Sore throat
  • Nausea and vomiting
  • Red skin lesions, sometimes with a purple center
  • Yellow skin or eyes
  • Loosening, peeling or blistering of the skin
  • Ulcers, white spots or sores on the lips or in the mouth
  • Chills
  • Muscle or joint pain
  • Cough
  • Itching
  • Diarrhea

If patients experience any side effects which are not listed above whilst taking Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, they should also seek medical help.

Dosage

When patients are prescribed Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir tablets to treat a chronic hepatitis C infection, they are usually advised to take two pink tablets once per day and one beige tablet twice per day. Typically, patients should take the two pink tablets together, in the morning, and one beige tablet in the morning and another beige tablet in the evening.

Sometimes, the combination medicine is made up of 12.5 mg of Ombitasvir, 75mg of Paritaprevir, 50mg of Ritonavir, and 250mg of Dasabuvir. However, the medicine can also be prescribed at a strength of 8.33mg of Ombitasvir, 50mg of Paritaprevir, 33.33mg of Ritonavir, and 200mg of Dasabuvir. Physicians will determine which strength of medication is best for the patient, based on their test results and symptoms.

When taking Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, patients should try to take their medicine at approximately the same time each day. This helps to keep the amount of medication in the body at a stable level and can lead to increased success rates for this type of treatment. In most instances, patients will be advised to take Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir tablet(s) with food.

Unless they are advised otherwise, patients should continue taking Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir for the full course of treatment. Patients may begin to feel better during this time but should still continue to take the medication as they have been instructed to.

If patients forget to take a dose of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, they may be able to catch up with their regular dosing schedule. This will depend on how long ago the missed dose should have been taken and when their next dose of medicine is due.

If the patient should have taken the missed dose less than twelve hours ago, they should take the pink tablets as soon as possible and then continue with their normal dosing schedule. However, if the missed dose should have been taken more than twelve hours ago, patients should skip the dose and take their next dose as normal.

If the missed dose should have been taken less than six hours ago, patients are usually advised to take the beige tablet as soon as they can. However, if the missed dose was due over six hours ago, patients should skip the dose and continue with their treatment as normal.

Patients should not take extra medicine or a double dose of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, even if an earlier dose has been missed. If patients are unsure how to take this medication or are unsure how to proceed after missing a dose, they should contact their physician or pharmacist for advice.

Potential Drug Interactions

As some medications can interact with one another, it may not be appropriate for patients to take certain medicines alongside Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir. For example, patients should not be given any of the following medicines alongside Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir:

  • Abiraterone
  • Dihydroergotamine
  • Alfuzosin
  • Eletriptan
  • Amifampridine
  • Encainide
  • Amiodarone
  • Elbasvir
  • Amisulpride
  • Dronedarone
  • Astemizole
  • Bepridil
  • Ergoloid Mesylates
  • Carbamazepine
  • Eplerenone
  • Cisapride
  • Enzalutamide
  • Colchicine
  • Conivaptan
  • Crizotinib
  • Efavirenz
  • Maraviroc
  • Ergonovine
  • Ivabradine
  • Ergotamine
  • Lurasidone
  • Ethinyl Estradiol
  • Methylergonovine
  • Etravirine
  • Midazolam
  • Flecainide
  • Nimodipine
  • Flibanserin
  • Mitotane
  • Fluconazole
  • Naloxegol
  • St John's Wort
  • Fosphenytoin
  • Nelfinavir
  • Gemfibrozil
  • Phenytoin
  • Grazoprevir
  • Nevirapine
  • Isavuconazonium Sulfate
  • Sildenafil
  • Lomitapide
  • Silodosin
  • Lovastatin
  • Rifampin
  • Mesoridazine
  • Riociguat
  • Methysergide
  • Phenobarbital
  • Ranolazine
  • Pimozide
  • Tolvaptan
  • Piperaquine
  • Triazolam
  • Primidone
  • Terfenadine
  • Propafenone
  • Venetoclax
  • Quinidine
  • Thioridazine
  • Romidepsin
  • Voriconazole
  • Simvastatin
  • Ziprasidone
  • Sparfloxacin

Furthermore, the use of the following medicines is not normally recommended alongside Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir:

  • Ado-Trastuzumab Emtansine
  • Enzalutamide
  • Afatinib
  • Eszopiclone
  • Alprazolam
  • Eluxadoline
  • Amiodarone
  • Etravirine
  • Amprenavir
  • Escitalopram
  • Anagrelide
  • Everolimus
  • Apixaban
  • Etoposide
  • Aprepitant
  • Erlotinib
  • Aripiprazole
  • Flecainide
  • Arsenic Trioxide
  • Folic Acid
  • Artemether
  • Fluoxetine
  • Ataluren
  • Fentanyl
  • Atazanavir
  • Fluticasone
  • Avanafil
  • Fosamprenavir
  • Axitinib
  • Fosaprepitant
  • Bedaquiline
  • Furosemide
  • Bepridil
  • Hydroxychloroquine
  • Boceprevir
  • Fusidic Acid
  • Bosentan
  • Gonadorelin
  • Bosutinib
  • Hydrocodone
  • Brexpiprazole
  • Histrelin
  • Bromocriptine
  • Garlic
  • Budesonide
  • Goserelin
  • Bupropion
  • Panobinostat
  • Buserelin
  • Pitolisant
  • Cabazitaxel
  • Pixantrone
  • Cabozantinib
  • Pimavanserin
  • Calcifediol
  • Palbociclib
  • Cariprazine
  • Pravastatin
  • Ceritinib
  • Pazopanib
  • Cilostazol
  • Ponatinib
  • Cladribine
  • Pasireotide
  • Clarithromycin
  • Prednisolone
  • Cobicistat
  • Oxycodone
  • Cobimetinib
  • Retapamulin
  • Conivaptan
  • Reboxetine
  • Conjugated Estrogens
  • Rifabutin
  • Cyclophosphamide
  • Prednisone
  • Cyclosporine
  • Dabigatran Etexilate
  • Zolpidem
  • Triptorelin
  • Propafenone
  • Vandetanib
  • Trabectedin
  • Quinine
  • Vilanterol
  • Dabrafenib
  • Triamcinolone
  • Regorafenib
  • Daclatasvir
  • Tacrolimus
  • Quinidine
  • Dactinomycin
  • Quercetin
  • Zuclopenthixol
  • Darunavir
  • Quetiapine
  • Dasatinib
  • Mifepristone
  • Daunorubicin
  • Morphine Sulfate Liposome
  • Deferasirox
  • Mexiletine
  • Degarelix
  • Metronidazole
  • Delamanid
  • Montelukast
  • Deslorelin
  • Morphine
  • Dexamethasone
  • Moxifloxacin
  • Digoxin
  • Nifedipine
  • Disopyramide
  • Iloperidone
  • Docetaxel
  • Orlistat
  • Dolutegravir
  • Irinotecan
  • Domperidone
  • Rifapentine
  • Donepezil
  • Nafarelin
  • Doxorubicin
  • Olaparib
  • Doxorubicin Hydrochloride Liposome
  • Nilotinib
  • Hydroxyzine
  • Omeprazole
  • Ibrutinib
  • Oxaliplatin
  • Idelalisib
  • Nitrofurantoin
  • Ifosfamide
  • Ondansetron
  • Irinotecan Liposome
  • Simeprevir
  • Ivacaftor
  • Sunitinib
  • Ivermectin
  • Sulpiride
  • Ixabepilone
  • Sumatriptan
  • Ketoconazole
  • Suvorexant
  • Lacosamide
  • Sorafenib
  • Lamivudine
  • Sonidegib
  • Lapatinib
  • Temsirolimus
  • Leuprolide
  • Tamsulosin
  • Levofloxacin
  • Topotecan
  • Sotalol
  • Levomilnacipran
  • Teniposide
  • Lidocaine
  • Testosterone
  • Lopinavir
  • Tamoxifen
  • Macitentan
  • Ticagrelor
  • Manidipine
  • Tadalafil
  • Metformin
  • Sertraline
  • Methotrexate
  • Vemurafenib
  • Sevoflurane
  • Venlafaxine
  • Methylenedioxymethamphetamine
  • Vorapaxar
  • Toremifene
  • Rilpivirine
  • Vinblastine
  • Riluzole
  • Voriconazole
  • Rivaroxaban
  • Vinflunine
  • Rosuvastatin
  • Vincristine Sulfate Liposome
  • Ruxolitinib
  • Vilazodone
  • Salmeterol
  • Vincristine

If doctors do prescribe any of the above medicines alongside Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, the patient's dose may be altered in order to try and reduce the risk of an interaction occurring.

Also, patients may be more likely to experience side effects if Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir is taken in conjunction with any of the following medicines:

  • Acenocoumarol
  • Medroxyprogesterone Acetate
  • Amitriptyline
  • Methamphetamine
  • Amprenavir
  • Lamotrigine
  • Cerivastatin
  • Levothyroxine
  • Clonazepam
  • Mestranol
  • Dalfopristin
  • Methadone
  • Delavirdine
  • Meperidine
  • Desipramine
  • Nefazodone
  • Desogestrel
  • Prasugrel
  • Didanosine
  • Opicapone
  • Dienogest
  • Paroxetine
  • Disopyramide
  • Olanzapine
  • Drospirenone
  • Risperidone
  • Dutasteride
  • Norgestimate
  • Estradiol Cypionate
  • Quinupristin
  • Estradiol Valerate
  • Tenofovir Disoproxil Fumarate
  • Ethynodiol Diacetate
  • Norgestrel
  • Etonogestrel
  • Norethindrone
  • Fosamprenavir
  • Imipramine
  • Theophylline
  • Levonorgestrel
  • Indinavir
  • Trazodone
  • Itraconazole
  • Warfarin
  • Mexiletine
  • Valproic Acid
  • Norelgestromin

Patients should be aware that Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir can interact with some foods, drinks, supplements, vitamins and over-the-counter medications. For example, patients should not consume the following when taking this medicine:

  • Grapefruit juice

Patients should inform their doctor if they are using any over-the-counter medicines, supplements or vitamins before they start taking Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir. They should also obtain medical advice before using any new medicines, vitamins or supplements once they have started receiving treatment.

Warnings

If patients have any other health problems, it may affect their treatment for a chronic hepatitis C infection. Similarly, their medical history may have an impact on their use of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir. Patients should discuss their health with their doctor before using this medicine. The following conditions can be particularly relevant if treatment with Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir is due to begin:

The effects of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir on pediatric patients are still unknown and, due to this, children and infants are not usually treated with this medicine.

If Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir is taken without Ribavirin, the medication is classed as a category B drug in terms of the risk to pregnant patients. This means that the risk of harm to the unborn fetus cannot be ruled out.

However, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir with Ribavirin is extremely dangerous for pregnant patients. Using this combination of medicines when pregnant should be avoided as harm may be caused to the fetus. If male patients impregnate a partner when using this combination of medicine, the fetus may develop birth defects.

If patients become pregnant whilst taking Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, with or without Ribavirin, they should inform their physician immediately.

It is not known whether Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir can be transmitted to an infant via breastmilk. Due to the risk of harm to the infant, patients are normally advised not to breastfeed whilst using this medication. Similarly, patients should not breastfeed if they are taking Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir alongside Ribavirin as there is a risk of harm to the infant.

If patients develop an allergic reaction whilst using Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, they will require emergency medical treatment. Symptoms of an allergic reaction may include:

  • Wheezing
  • Difficulty swallowing
  • Difficulty breathing
  • Hives
  • Rash on the skin
  • Itching
  • Hoarseness
  • Swelling of the face, lips, tongue, mouth, throat and/or hands

Storage

When storing Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir at home, patients should follow the medication guidelines. In general, this medicine can usually be kept at room temperature but should always be stored in a closed container. Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir should also be kept away from heat, moisture and direct light.

It's important that patients use a secure location to store this medicine and prevent children and/or pets from gaining access to it.

If the medication reaches its expiration date or patients are advised to stop using it, they will need to dispose of it carefully. Patients should contact their physician's office or pharmacist and make use of a designated medicine disposal service.

Summary

Although a hepatitis C infection may not cause many symptoms at first, it's likely that patients will become symptomatic without treatment. If the infection is allowed to persist, patients could suffer serious complications, such as liver disease and/or liver cancer.

Despite the potential severity of a chronic hepatitis C infection, the condition can be successfully treated in the vast majority of cases. Once doctors have established which genome of the virus has caused the condition, the appropriate combination of medicine can be prescribed. When patients are treated with Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, they should notice a reduction in their symptoms whilst taking the medication. However, patients will need to continue taking Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir for the full course of treatment in order to ensure the infection is fully resolved.